PolyPid's D-PLEX100 shows lower bacterial burden in pooled surgical-site infection analysis
PYPD•PolyPid said D-PLEX100 with standard care showed lower bacterial burden and later onset in breakthrough surgical-site infections than standard care alone, in pooled exploratory results from three randomized trials it will present at IDWeek on October 22, 2026.
1. Pooled trial findings
PolyPid will present exploratory pooled microbiology results from three randomized trials of D-PLEX100 at IDWeek in Washington, D.C., on October 22, 2026. Multidrug-resistant organisms occurred in similar proportions across treatment groups, and there was no statistically significant difference in doxycycline resistance.
